ErpeLips® Expands ACS Biomed's HSV Product Portfolio
New topical formulation extends the company's proprietary HSV platform and strengthens its international commercial offering.
ACS Produzioni Biomed S.r.l. (“ACS Biomed”), an Italian biotechnology company developing innovative topical solutions for Herpes Simplex Virus (HSV) infections, has expanded its product portfolio with the introduction of ErpeLips®, a formulation specifically developed for the management of recurrent labial herpes (HSV-1).
Built on the same proprietary nanoemulsion technology that underpins ErpeCream®, ErpeLips® has been designed to provide a practical and scientifically supported solution for one of the most common viral skin conditions worldwide. The launch represents an important milestone in ACS Biomed's strategy of developing an integrated product platform capable of addressing different manifestations of HSV infections through a common technological foundation.
The addition of ErpeLips® strengthens the company's commercial offering while creating new opportunities for international distributors seeking innovative healthcare products supported by proprietary formulation technology.
A Technology Platform Designed for HSV Management
ErpeLips® has been specifically formulated for topical application to recurrent herpes labialis and incorporates the same patented oil-in-water nanoemulsion platform used in ErpeCream®. The formulation combines selected botanical extracts with a proprietary delivery system designed to optimise product stability and topical application.
The product has been developed as a compact 3 ml applicator, allowing convenient, hygienic and discreet use throughout the different stages of recurrent cold sore episodes.
Like ErpeCream®, ErpeLips® has been developed with a focus on product quality, stability and international commercialisation, supporting ACS Biomed's long-term objective of building a differentiated portfolio of HSV-focused healthcare products.
Strengthening the Commercial Portfolio
The introduction of ErpeLips® allows ACS Biomed to offer distributors and commercial partners a broader product range addressing both labial HSV-1 and genital HSV-2 applications.
For international distribution partners, this integrated portfolio creates opportunities to develop a single commercial relationship covering multiple segments within the HSV topical care market. The shared formulation technology, manufacturing processes and regulatory strategy also provide operational efficiencies that support future market expansion.
This portfolio approach forms part of ACS Biomed's broader international strategy, which combines product innovation with long-term commercial partnerships across Europe, Latin America and additional markets currently under evaluation.
Supporting Long-Term Growth
Herpes simplex virus remains one of the most prevalent viral infections worldwide, affecting billions of people and creating continued demand for innovative topical healthcare solutions.
Through the introduction of ErpeLips®, ACS Biomed continues to expand a proprietary technology platform designed to support both commercial growth and future scientific development. Together with ErpeCream®, the product strengthens the company's ability to offer differentiated solutions based on proprietary formulation technology while supporting ongoing discussions with distributors, healthcare organisations and strategic partners.
As ACS Biomed continues its international expansion, ErpeLips® represents another important step in building a comprehensive HSV product portfolio capable of supporting both current commercial opportunities and the company's long-term pharmaceutical development strategy.